What podcasts say about Viswa Colluru
Every statement, with the speaker, the exact quote and the moment it was said.
What Viswa Colluru has said on podcasts
17 statements · 6 positive · 7 negative · 4 neutral
Only a small fraction of biological compounds have been discovered
“it's expected that there's about 1 to 10 billion.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:45:14
Large impactful drug companies must develop important medicines
“if you want to build a large and impactful drug company, the rule is super simple. Make drugs and make drugs that matter.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:46:42
Cancer comprises thousands of distinct diseases
“cancer isn't one disease. Yeah. And it's... thousands of diseases.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:47:36
Common diseases are difficult to treat because they are complex and multifactorial
“Common diseases are difficult for two reasons. They're complex and multifactorial.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:48:13
Approximately 10–15% of patients do not respond to GLP-1 drugs.
“10 to 15 percent of patients don't respond to GLP-1s.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:48:50
Ten to fifteen percent of patients do not respond to GLP-1 drugs
“10 to 15 percent of patients don't respond to GLP-1s.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:48:50
Enveda has not yet begun cancer-treatment efforts
“we haven't started efforts on trying to treat cancer yet.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:50:12
Enveda’s first two drugs target asthma, eczema, and post-GLP-1 weight management
“Our first two drugs are hitting exactly those problems.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:50:51
Enveda’s second molecule aims to help 55 million Americans after GLP-1 use
“giving 55 million people in America an off-ramp over the next seven years that will have taken a GLP-1”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:51:24
At least 99% of AI-designed chemistry is constrained by physical feasibility.
“99% or more of the chemistry that any particular model comes up with is constrained by the physics and energetics of putting it together.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:52:53
AI currently performs poorly at manipulating physical-world processes.
“AI is really bad at moving things in the physical world.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:53:21
Pilgrim aims to deploy biotechnology technologies to warfighters quickly
“the idea really is to build up what is a really substantial wedge and get technologies like this into the hands of the warfighter today.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:56:08
Biological-security incidents have increased dramatically
“the rate and the incidents around bio have grown dramatically”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:57:52
Pilgrim’s platform will autonomously detect viruses across multiple media
“the core platform being able to detect viruses autonomously, that's just going to be deployed across all of these different types of media, wastewater, clinical, everything.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:59:55
Pilgrim’s platform will autonomously detect viruses across wastewater, clinical, and other media.
“the core platform being able to detect viruses autonomously, that's just going to be deployed across all of these different types of media, wastewater, clinical, everything.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 1:59:55
Current airborne biological-threat detection takes about a week
“the current timeline to even detect a threat in the air is like a week.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 2:00:57
Current airborne biological-threat detection can take approximately one week.
“the current timeline to even detect a threat in the air is like a week.”
Open the episode · 4 Tech Arguments (Number 3 Will Shock You), Mansion Section, John Arnold Joins | Viswa Colluru, Jake Adler, Adam KorsunskyListen at 2:00:57
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.